Abstract

The systemic management of advanced adrenal cancer remains a major therapeutic dilemma as it is both highly resistant to systemic agents and very rare epithelial neoplasm making clinical investigation a significant challenge. The role of mitotane, systemic chemotherapy and novel targeted agents are reviewed.

Links

Publisher Full Text

Authors

Dreicer R

Institution

Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA. Dreicer@ccf.org

Source

Journal of surgical oncology 106:5 2012 Oct 1 pg 643-6

MeSH

Adrenal Gland Neoplasms
Animals
Humans

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22488742